Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab

Clinical Cancer Research

Volumn 15, Issue 12, 2009, Pages 4147-4156

  Yao, Evelyn ^a   Zhou, Wei ^a   Lee Hoeflich, Si Tuen ^a   Truong, Tom ^a   Haverty, Peter M ^a   Eastham Anderson, Jeffrey ^a   Lewin Koh, Nicholas ^a   Gunter, Bert ^a   Belvin, Marcia ^a   Murray, Lesley J ^a   Friedman, Lori S ^a   Sliwkowski, Mark X ^a   Hoeflich, Klaus P ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; GDC 0941; LAMININ; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; NEU DIFFERENTIATION FACTOR; PERTUZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CHEMOSENSITIVITY; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL LINE, TUMOR; ENZYME INHIBITORS; HUMANS; INDAZOLES; MICE; MICE, NUDE; QUINAZOLINES; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; SIGNAL TRANSDUCTION; SULFONAMIDES; TAXOIDS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 67449168372     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-2814     Document Type: Article

References (45)

1. Sugimoto Y, Whitman M, Cantley LC, Erikson RL. Evidence that the Rous sarcoma virus transforming gene product phosphorylates phosphatidylinositol and diacylglycerol. Proc Natl Acad Sci U S A 1984;81:2117-2121 (Pubitemid 14146614)
2. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev 2006;7:606-619 (Pubitemid 44100518)
3. Bader AG, Kang S, Zhao L, Vogt PK. Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer 2005;5:921-929 (Pubitemid 41766781)
4. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004;304:554. (Pubitemid 38541907)
5. Wishart MJ, Dixon JE. PTEN and myotubularin phosphatases: from 3-phosphoinositide dephosphorylation to disease. Trends Cell Biol 2002;12:579-585 (Pubitemid 35461856)
6. Marone R, Cmiljanovic V, Giese B, Wymann MP. Targeting phosphoinositide 3-kinase: moving towards therapy. Biochim Biophys Acta 2008;1784:159-185
7. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-137 (Pubitemid 33674041)
8. Lee-Hoeflich ST, Crocker L, Yao E, et al. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res 2008;68:5878-5887
9. Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 2002;62:4132-4141 (Pubitemid 34791085)
10. Hsieh AC, Moasser MM. Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br J Cancer 2007;97:453-457 (Pubitemid 47258458)
11. Fedi P, Pierce JH, di Fiore PP, Kraus MH. Efficient coupling with phosphatidylinositol 3-kinase, but not phospholipase C γ or GTPase-activating protein, distinguishes ErbB-3 signaling from that of other ErbB/EGFR family members. Mol Cell Biol1994;14:492-500.
12. Motoyama AB, Hynes NE, Lane HA. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides. Cancer Res 2002;62:3151-3158 (Pubitemid 34602408)
13. Berns K, Horlings HM, Hennessy BT, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007;12:395-402. (Pubitemid 47539306)
14. Nagata Y, Lan KH, Zhou X, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004;6:117-127 (Pubitemid 39485684)
15. Debnath J, Brugge JS. Modelling glandular epithelial cancers in three-dimensional cultures. Nat Rev Cancer 2005;5:675-688 (Pubitemid 41486361)
16. Nelson CM, Bissell MJ. Of extracellular matrix, scaffolds, and signaling: tissue architecture regulates development, homeostasis, and cancer. Ann Rev Cell Dev Biol 2006;22:287-309. (Pubitemid 44777998)
17. Yamada KM, Cukierman E. Modeling tissue morphogenesis and cancer in 3D. Cell 2007;130:601-610 (Pubitemid 47268064)
18. Lee GY, Kenny PA, Lee EH, Bissell MJ. Three-dimensional culture models of normal and malignant breast epithelial cells. Nat Methods 2007;4:359-365 (Pubitemid 46766981)
19. Folkes AJ, Ahmadi K, Alderton WK, et al. The Identification of 2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl) -4-morpholin-4-ylthieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J Med Chem 2008;51:5522-5532
20. Agus DB, Akita RW, Fox WD, et al. Targeting ligand activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2002;2:127-137 (Pubitemid 41039113)
21. Gelmon KA, Fumoleau P, Verma S, et al. Results of a phase II trial of trastuzumab and pertuzumab in patients with HER2-positive metastatic breast cancer who had progressed during trastuzumab therapy. JClin Oncol 2008;26.
22. Holmes WE, Sliwkowski MX, Akita RW, et al. Identification of heregulin, a specific activator of p185erbB2. Science New York NY 1992;256:1205-1210
23. Anton H. Calculus: a new horizon. 6th Ed. New York: Wiley; 1984. p. 870-872
24. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005;102:15545-15550 (Pubitemid 41528093)
25. Forbes S, Clements J, Dawson E, et al. Cosmic 2005. Br J Cancer 2006;94:318-322
26. Kurebayashi J, Otsuki T, Tang CK, et al. Isolation and characterization of a new human breast cancer cell line, KPL-4, expressing the Erb B family receptors and interleukin-6. Br J Cancer 1999;79:707-717 (Pubitemid 29082094)
27. Neve RM, Chin K, Fridlyand J, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006;10:515-527 (Pubitemid 44854747)
28. Kenny PA, Lee GY, Myers CA, et al. The morphologies of breast cancer cell lines in three-dimensional assays correlatewith their profiles of gene expression. Mol Oncol 2007;1:84-96. (Pubitemid 46776616)
29. Sternlicht MD, Sunnarborg SW, Kouros-Mehr H, Yu Y, Lee DC, Werb Z. Mammary ductal morphogenesis requires paracrine activation of stromal EGFR via AD-AM17-dependent shedding of epithelial amphiregulin. Development 2005;132:3923-3933 (Pubitemid 41410256)
30. Schaefer G, Fitzpatrick VD, Sliwkowski MX. γ-Heregulin: a novel heregulin isoform that is an autocrine growth factor for the human breast cancer cell line, MDA-MB-175. Oncogene 1997;15:1385-1394 (Pubitemid 27437828)
31. Wang F, Hansen RK, Radisky D, et al. Phenotypic reversion or death of cancer cells by altering signaling pathways in three-dimensional contexts. J Natl Cancer Inst 2002;94:1494-1503 (Pubitemid 35243746)
32. Liu H, Radisky DC, Wang F, Bissell MJ. Polarity and proliferation are controlled by distinct signaling pathways downstream of PI3-kinase in breast epithelial tumor cells. J Cell Biol 2004;164:603-612 (Pubitemid 38233321)
33. Sergina NV, Rausch M, Wang D, et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 2007;445:437-441 (Pubitemid 46160912)
34. Moasser MM. Targeting the function of the HER2 oncogene in human cancer therapeutics. Oncogene 2007;26:6577-6592 (Pubitemid 47573679)
35. Xia W, Liu LH, Ho P, Spector NL. Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016. Oncogene 2004;23:646-653 (Pubitemid 38241266)
36. Liu H, Fan Q, Zhang Z, Li X, Yu H, Meng F. Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers. Human Pathology 2008;39:167-174
37. Pegram MD, Konecny GE, O'Callaghan C, Beryt M, Pietras R, Slamon DJ. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 2004;96:739-749 (Pubitemid 38771819)
38. Azambuja E, Durbecq V, Rosa DD, et al. HER-2 overexpression/amplification and its interaction with taxane-based therapy in breast cancer. Ann Oncol 2008;19:223-232 (Pubitemid 351201701)
39. Debnath J, Mills KR, Collins NL, Reginato MJ, Muthuswamy SK, Brugge JS. The role of apoptosis in creating and maintaining luminal space within normal and oncogene-expressing mammary acini. Cell 2002;111:29-40.
40. Weaver VM, Lelievre S, Lakins JN, et al. β 4 integrin-dependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium. Cancer Cell 2002;2:205-216 (Pubitemid 41043976)
41. Huang HE, Chin SF, Ginestier C, et al. A recurrent chromosome breakpoint in breast cancer at the NRG1/neuregulin 1/heregulin gene. Cancer Res 2004;64:6840-6844 (Pubitemid 39330987)
42. Li Q, Ahmed S, Loeb JA. Development of an autocrine neuregulin signaling loop with malignant transformation of human breast epithelial cells. Cancer Res 2004;64:7078-7085 (Pubitemid 39331020)
43. Montero JC, Rodriguez-Barrueco R, Ocana A, Diaz-Rodriguez E, Esparis-Ogando A, Pandiella A. Neuregulins and cancer. Clin Cancer Res 2008;14:3237-3241
44. Meiners S, Brinkmann V, Naundorf H, Birchmeier W. Role of morphogenetic factors in metastasis of mammary carcinoma cells. Oncogene 1998;16:9-20. (Pubitemid 28043504)
45. O'Shaughnessy J, Blackwell KL, Burstein H, et al. A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy. ASCO Meeting Abstracts 2008;26:1015.